Scientists reprogram immune cells to hunt down common cancer mutations
Disease control
Recruiting now
This is a first-in-human study testing a new type of personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The therapy involves collecting a patient's own immune cells (T cells), genetically engineering them in a lab to …
Phase: PHASE1 • Sponsor: Ting Deng • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC